• Bristol-Myers Squibb Co., of New York, and Tsinghua University in Beijing, China, said they formed a multiyear strategic partnership. Under the agreement, BMS will fund research efforts at the university's School of Life Sciences to identify and validate targets in oncology and immunoscience. The collaboration also will focus on structural biology research, the science of mapping the 3D protein structure of biological molecular targets that could serve as the basis for future drug discovery projects. In separate news, BMS said the FDA approved its biologics manufacturing facility in Devens, Mass., for commercial production of arthritis drug Orencia (abatacept).